HMGB1/HMG-1 Antibody (1D5)

This product is produced by and distributed for Abnova, a company based in Taiwan.

HMGB1 and HMGB2 are part of the chromatin non-histone high mobility group proteins 1 and 2. HMGB1 and HMGB2 (containing multiple HMG-boxes) are conserved domains of 80 amino acids which mediate the DNA binding of many proteins. HMG box domains recognize DNA structure. Both HMGB1 and HMGB2 contain a N-terminal HMG box, a central HMG box, and an acidic carboxy terminus. The acidic tails of HMGB1 and HMGB2 contain multiple serine residues which match the phosphorylation consensus sites of casein kinase II, and phosphorylation of this domain appears to be important for proper functioning of these proteins. HMGB1 and HMGB2 have been shown to facilitate the binding of various sequence-specific transcription factors to their respective DNA binding sites. HMGB1 and HMGB2 may also serve as architectural factors that recognize and mediate DNA structural changes that accompany various events such as DNA repair, transcription, and replication.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Rat.

We have publications tested in 1 application: MiAr.

Showing Publications 1 - 7 of 7.

Publications using H00003146-M02	Applications	Species
Tonner H, Hunn S, Auler N et al. A Monoclonal Anti-HMGB1 Antibody Attenuates Neurodegeneration in an Experimental Animal Model of Glaucoma International journal of molecular sciences 2022-04-07 [PMID: 35456925] (MiAr, Rat)	MiAr	Rat
Pascale H, Patrick R, Stephanie D et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J Immunother Cancer. 2021-03-15 [PMID: 33712445]
Demoulin S, Herfs M, Somja J et al. HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells. Int J Cancer. 2014-11-26 [PMID: 25492101]
Ko HK, Hsu WH, Hsieh CC et al. High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers. Respirology. 2013-12-24 [PMID: 24372740]
Hirano H, Yoshioka T, Yunoue S et al. TLR4, IL-6, IL-18, MyD88 and HMGB1 are highly expressed in intracranial inflammatory lesions and the IgG4/IgG ratio correlates with TLR4 and IL-6. Neuropathology. 2012-03-13 [PMID: 22414145]
Kijanka G, Hector S, Kay EW et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 59(1):69-78. 2010-01-01 [PMID: 19828471]
Kruger B, Krick S, Dhillon N et al. Donor Toll-like receptor 4 contributes to ischemia reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 106(9):3390-5. 2009-03-03 [PMID: 19218437]

Array H00003146-M02

• HMGB1/HMG-1 Antibodies
• HMGB1/HMG-1 Antibody Pair
• HMGB1/HMG-1 ELISA Kits
• HMGB1/HMG-1 Lysate
• HMGB1/HMG-1 Proteins
• HMGB1/HMG-1 Proteins and Enzyme